UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box L450
`Alexandria, Virginia 223L3-l450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`18/342,553
`
`06/27/2023
`
`Ben Merritt
`
`111552.8018.USll
`
`6799
`
`25096
`7590
`05/07/2024
`PERKINS COIE LLP - SEA General
`PATENT-SEA
`P.O. BOX 1247
`SEATTLE, WA 98111-1247
`
`EXAMINER
`
`RASSA VONG, ERIC
`
`ART UNIT
`
`PAPER NUMBER
`
`3781
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`05/07/2024
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`patentprocurement@perkinscoie.com
`
`PTOL-90A (Rev. 04/07)
`
`Imperative Care v. Inari Medical
`U.S. Patent 11,974,910
`Imperative Care Ex. 1002
`
`-1-
`
`

`

`APPLICATION NO.
`
`18/342,553
`
`ISSUE DATE
`
`07-May-2024
`
`PATENT NO.
`
`11974910
`
`PERKINS COIE LLP - SEA General
`PATENT-SEA
`P.O. BOX 1247
`SEATTLE, WA98111-1247
`
`EGRANT NOTIFICATION
`
`Your electronic patent grant (eGrant) is now available, which can be accessed via Patent Center at https://
`patentcenter.uspto.gov
`
`The electronic patent grant is the official patent grant under 35 U.S.C. 153. For more information, please visit
`https://www.uspto.gov/electronicgrants
`
`page 1 of 1
`
`-2-
`
`

`

`UNITED STATES PA TENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONERFORPATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`18/342,553
`
`ISSUE DATE
`
`05/07/2024
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`11974910
`
`111552.8018.USl 1
`
`6799
`
`04/17/2024
`7590
`25096
`PERKINS COIE LLP - SEA General
`PATENT-SEA
`P.O. BOX 1247
`SEATTLE, WA 98111-1247
`
`ISSUE NOTIFICATION
`The projected patent number and issue date are specified above. The patent will issue electronically. The
`electronically issued patent is the official patent grant pursuant to 35 U.S.C. § 153. The patent may be accessed
`on or after the issue date through Patent Center at https://patentcenter.uspto.gov/. The patent will be available in
`both the public and the private sides of Patent Center. Further assistance in electronically accessing the patent,
`or about Patent Center, is available by calling the Patent Electronic Business Center at 1-888-217-9197.
`
`The USPTO is implementing electronic patent issuance with a transition period, during which period the
`USPTO will mail a ceremonial paper copy of the electronic patent grant to the correspondence address of
`record. Additional copies of the patent (i.e., certified and presentation copies) may be ordered for a fee from the
`USPTO's Certified Copy Center at https://certifiedcopycenter.uspto.gov/index.html. The Certified Copy Center
`may be reached at (800)972-6382.
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is O day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Center (https://
`patentcenter.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office
`of Patent Legal Administration at ( 571 )-272-7702. Questions relating to issue and publication fee payments should
`be directed to the Application Assistance Unit (AAU) of the Office of Patents Stakeholder Experience (OPSE),
`Stakeholder Support Division (SSD) at (571)-272-4200.
`
`IR103 (Rev. 10/09)
`
`-3-
`
`

`

`INVENTOR(s) (Please see PATENT CENTER site https://patentcenter.uspto.gov for additional inventors):
`
`Ben Merritt, San Clemente, CA;
`Jacqueline Macias, Fullerton, CA;
`Brian Michael Strauss, San Clemente, CA;
`Thomas Tu, Louisville, KY;
`John Coleman Thress, Capistrano Beach, CA;
`
`APPLICANT( s) (Please see PA TENT CENTER site https://patentcenter.uspto.gov for additional applicants):
`
`Inari Medical, Inc., Irvine, CA;
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage and facilitate business investment. To learn more about why the USA is the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.
`
`IR103 (Rev. 10/09)
`
`-4-
`
`

`

`Receipt date: 08/14/2023
`
`18/342,553 - GAU: 3781
`
`Doc code: IDS
`Doc description: Information Disclosure Statement (IDS) Filed
`
`PTO/SB!08a (01-10)
`Approved for use through 07/31120·12. 0MB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Ac! of ·1995, no persons are required to respond !o a ,,ollection of inforniation uniess it contains a valid 0MB oonlrol number
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPUCANT
`(Not for submission under 37 CFR 1.99}
`
`Application Number
`18/342,553- Conf # 6799
`Filing Date
`June 27, 2023
`First Named Inventor
`Ben Merritt
`3781
`Art Unit
`!'s!rii. I et ~S5i!~l ll':!~i
`Examiner Name
`Attorney Docket Number -1115s2.ao1a.us-11
`
`Erir.~ Rassavong·
`
`Examiner Cite
`Initial'
`No
`
`Patent Number
`
`Issue Date
`
`Name of Patentee or 1-\pplicant of cited
`Document
`
`Pages, Columns, Lines, VVhere
`Relevant Passages or Relevant
`Figures Appear
`
`U.S. PA TENTS AND PUBUCA T!ONS
`
`,.
`
`I
`
`Change(s
`
`I
`nt,
`to documc
`/J.E._/
`4
`)/29/202
`
`1.
`
`2.
`
`I 3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`07-27-2023
`20230233311
`10-04-2007
`20070233043
`8343167 01/201 :i Q~
`!il~ iii!Qii!B
`8568465
`10-29-2013
`08-03-2023
`20230241302
`08-03-2023
`20230240705
`08-03-2023
`20230240706
`0·1-22-2019
`10183159
`
`Merritt et al.
`Dayton et al.
`Henson
`Freudenthal et al.
`Merritt et al.
`Rosenbluth et ai.
`
`Rosenbluth et ai.
`Nobles et aL
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`Initial''
`No Number'
`
`Publication Date
`
`Pages, Columns,
`Name of Patentee or Applicant of cited Document Lines. V\lt1ere
`Relevant Passages
`or Relevant Figures
`Appear
`
`·rs
`
`1. W0202314 7353
`
`08-03-2023
`
`lnari Medical, Inc.
`
`NON-PATENT LITERATURE DOCUMENTS
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, rs
`Examiner Cite
`No magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume .. issue nl.l!nber(s), publisher, city and/or country
`Initials*
`where published.
`
`EXAMINER SIGNATURE
`I 10/25/2023
`Examiner Signature /ERIC jRASSAVONG/
`(10 /25/202toate Considered
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line
`through a citation if not in conformance and not considered. Include copy oi'this form with next communication
`to applicant.
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-
`letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the
`serial number of the patent document. 4 Kind of document by the appropriate symbols ;is indicated on tt1e document under WIPO Standard
`ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.
`
`163380412.1
`
`1
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH"
`
`/E.R./
`
`-5-
`
`

`

`UNITED STATES PA TENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONERFORPATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`18/342,553
`
`06/27/2023
`
`Ben Merritt
`
`111552.8018.US 11
`
`6799
`
`03/28/2024
`7590
`25096
`PERKINS COIE LLP - SEA General
`PATENT-SEA
`P.O. BOX 1247
`SEATTLE, WA 98111-1247
`
`EXAMINER
`
`RAS SA VONG, ERIC
`
`ART UNIT
`
`PAPER NUMBER
`
`3781
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`03/28/2024
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`patentprocurement@perkinscoie.com
`
`PTOL-90A (Rev. 04/07)
`
`-6-
`
`

`

`Supplemental
`Notice of Allowability
`
`Application No.
`18/342,553
`Examiner
`ERIC RASSAVONG
`
`Applicant(s)
`Merritt et al.
`Art Unit
`3781
`
`I AIA (FITF) Status
`
`Yes
`
`-- The MAILING DA TE of this communication appears on the cover sheet with the correspondence address-(cid:173)
`All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included
`herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS
`NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative
`of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.
`
`1.~ This communication is responsive to Printer Rush filed on 03/19/2024.
`DA declaration(s)/affidavit(s) under 37 CFR 1.130(b) was/were filed on __ .
`
`2.0 An election was made by the applicant in response to a restriction requirement set forth during the interview on __ ; the
`restriction requirement and election have been incorporated into this action.
`
`3.~ The allowed claim(s) is/are 1-17, 19 and 21-22. As a result of the allowed claim(s), you may be eligible to benefit from the Patent
`Prosecution Highway program at a participating intellectual property office for the corresponding application. For more information
`, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.
`
`4.0 Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
`Certified copies:
`c) D None of the:
`b) 0 Some*
`a) □All
`1. D Certified copies of the priority documents have been received.
`2. D Certified copies of the priority documents have been received in Application No. __ .
`3. D Copies of the certified copies of the priority documents have been received in this national stage application from the
`International Bureau (PCT Rule 17.2(a)).
`
`* Certified copies not received: __ .
`
`Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements
`noted below. Failure to timely comply will result in ABANDONMENT of this application.
`THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.
`
`5.0 CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
`D
`including changes required by the attached Examiner's Amendment/ Comment or in the Office action of
`Paper No./Mail Date __ .
`Identifying indicia such as the application number {see 37 CFR 1.84{c)) should be written on the drawings in the front {not the back) of each
`sheet. Replacement sheet{s) should be labeled as such in the header according to 37 CFR 1.121{d).
`
`6.0 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the
`attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.
`
`Attachment(s)
`1. D Notice of References Cited (PTO-892)
`2.~ Information Disclosure Statements (PTO/SB/08),
`Paper No./Mail Date
`.
`3. 0 Examiner's Comment Regarding Requirement for Deposit
`of Biological Material
`.
`4.0 Interview Summary (PTO-413),
`Paper No./Mail Date.
`/E.R./
`Examiner, Art Unit 3781
`
`5. 0 Examiner's Amendment/Comment
`6. 0 Examiner's Statement of Reasons for Allowance
`
`7. OOther __
`
`/SUSAN S SU/
`Primary Examiner, Art Unit 3781
`
`U.S. Patent and Trademark Office
`PTOL-37 (Rev. 08-13)
`
`Notice of Allowability
`
`Part of Paper No./Mail Date 20240325
`
`-7-
`
`

`

`Receipt date: 03/12/2024
`
`18/342,553 - GAU: 3781
`
`Doc code: IDS
`Doc description: Information Disclosure Statement (IDS) Filed
`
`PTO/SB/08a (01-10)
`Approved for use through 07/31/2012. 0MB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`(Not for submission under 37 CFR 1.99)
`
`Application Number
`18/342,553- Conf # 6799
`Filing Date
`June 27, 2023
`First Named Inventor
`Ben Merritt
`Art Unit
`3781
`Examiner Name
`Eric Rassavong
`Attorney Docket Number 111552.8018.US11
`
`Examiner Cite
`No
`Initial*
`
`Patent Number
`
`Issue Date
`
`Name of Patentee or Applicant of cited
`Document
`
`Pages, Columns, Lines, Where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S. PA TENTS AND PUBLICATIONS
`
`11918244
`11918243
`6059745
`20030225379
`20050131387
`5951539
`11213356
`
`7905877
`20010041881
`20110264132
`20200054861
`
`20190223893
`20190328411
`20240074771
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`12.
`
`13.
`
`14.
`
`15.
`
`16.
`
`03-05-2024
`03-05-2024
`05-09-2000
`12-04-2003
`06-16-2005
`09-14-1999
`01-04-2022
`
`03-15-2011
`11-15-2001
`10-27-2011
`02-20-2020
`
`07-25-2019
`10-31-2019
`03-07-2024
`
`Marchand et al.
`Marchand et al.
`Gelbfish
`Schaffer et al.
`Pursley
`Nita et al.
`Tanner et al.
`
`Jilnenez et al.
`SARGE et al.
`Strauss et al.
`Korkuch et al.
`
`GILVARRY et al.
`VALE et al.
`Quick et al.
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`Number3
`Initial*
`No
`
`Publication Date
`
`Name of Patentee or Applicant of cited Document
`
`T5
`
`Pages, Columns,
`Lines, Where
`Relevant Passages
`or Relevant Figures
`Appear
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`165925361.1
`
`1
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.R./
`
`-8-
`
`

`

`Receipt date: 03/12/2024
`
`18/342,553 - GAU: 3781
`
`Doc code: IDS
`Doc description: Information Disclosure Statement (IDS) Filed
`
`PTO/SB/08a (01-10)
`Approved for use through 07/31/2012. 0MB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`(Not for submission under 37 CFR 1.99)
`
`Application Number
`18/342,553- Conf # 6799
`Filing Date
`June 27, 2023
`First Named Inventor
`Ben Merritt
`Art Unit
`3781
`Examiner Name
`Eric Rassavong
`Attorney Docket Number 111552.8018.US11
`
`NON-PATENT LITERATURE DOCUMENTS
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, Ts
`Examiner Cite
`Initials*
`No magazine, journal, serial, symposium, catalog, etc.), dale, page(s), volume-issue number(s), publisher, city and/or country
`where published.
`
`English translation of Japanese Office Action received for JP Application No. 2022-574456, Applicant: lnari
`Medical, Inc, Date of Mailing: January 23, 2024, 12 pages.
`
`Chinese First Office Action received for CN Application No. 201980067623.1, Applicant: lnari Medical, Inc.,
`Date of Mailing: January 31, 2024, 10 pages.
`
`International Search Report and Written Opinion for International App. No. PCT/US23/73765; Date of Filing:
`September 8, 2023, Applicant: lnari Medical, Inc., Date of Mailing: February 28, 2024, 7 pages.
`
`International Search Report and Written Opinion for International App. No. PCT/US23/69892; Date of Filing:
`July 10, 2023, Applicant: lnari Medical, Inc., Date of Mailing: February 29, 2024, 12 pages.
`
`EXAMINER SIGNATURE
`I 03/25/2024
`(03/25/202f,:oate Considered
`Examiner Signature /ERIC IRASSAVONG/
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line
`through a citation if not in conformance and not considered. Include copy of this form with next communication
`to applicant.
`1 See Kind Codes of US PTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-
`letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the
`serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard
`ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.
`
`CERTIFICATION STATEMENT
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`D That each item of information contained in the information disclosure statement was first cited in any communication from
`a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information
`disclosure statement. See 37 CFR 1.97(e) (1 ).
`
`OR
`
`D That no item of information contained in the information disclosure statement was cited in a communication from a foreign
`patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making
`reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual
`designated in 37 CFR 1.56( c) more than three months prior to the filing of the information disclosure statement. See 37
`CFR 1.97(e) (2).
`D See attached certification statement.
`
`[8J Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`D None
`
`165925361.1
`
`2
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH_
`
`/E.R./
`
`-9-
`
`

`

`Receipt date: 03/12/2024
`
`18/342,553 - GAU: 3781
`
`Doc code: IDS
`Doc description: Information Disclosure Statement (IDS) Filed
`
`PTO/SB/08a (01-10)
`Approved for use through 07/31/2012. 0MB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`(Not for submission under 37 CFR 1.99)
`
`Application Number
`18/342,553- Conf # 6799
`Filing Date
`June 27, 2023
`First Named Inventor
`Ben Merritt
`Art Unit
`3781
`Examiner Name
`Eric Rassavong
`Attorney Docket Number 111552.8018.US11
`
`It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is
`respectfully requested to consider the listed references. This Information Disclosure Statement is not to be construed as a
`representation that: (i) a search has been made; (ii) additional information that may be material to the examination of this
`application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
`or (iv) the cited information is, or is considered to be, material to patentability. In addition, Applicant does not admit that any
`enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate
`that any such reference is not prior art.
`
`COPIES OF REFERENCES
`
`In accordance with 37 C.F.R. § 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications.
`Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 C. F.R. § 1.98(a)(2).
`
`SIGNATURE
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`I 2024-03-12
`I /Matthew S. Williams/
`I Date (YYYY-MM-DD)
`Signature
`I Registration Number
`I Matthew S. Williams
`I 11,516
`Name/Print
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public
`which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection
`is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the US PTO. Time
`will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for
`reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce,
`P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
`Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`165925361.1
`
`3
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH_
`
`/E.R./
`
`-10-
`
`

`

`UNITED STATES PATENT AND TRADEMARK 0FFIGE
`
`NUMBER
`18/342,553
`
`FILING or
`371(c)DATE
`06/27/2023
`
`GRPART
`UNIT
`3781
`
`FIL FEE REC'D
`1820
`
`25096
`PERKINS COIE LLP - SEA General
`PATENT-SEA
`P.O. BOX 1247
`SEATTLE, WA98111-1247
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Vrrginia 22313-1450
`www.uspto.gov
`
`ATTY.DOCKET.NO
`111552.8018.USll
`
`TOT CLAIMS IND CLAIMS
`20
`3
`CONFIRMATION NO. 6799
`UPDATED FILING RECEIPT
`llllllllllllllllllllllllllll~~~~~~~[~[~lmtlll~~lll lllll 111111111111111111
`
`Date Mailed: 03/20/2024
`
`Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for
`examination in due course. Applicant will be notified as to the results of the examination. Any correspondence
`concerning the application must include the following identification information: the U.S. APPLICATION NUMBER,
`FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are
`subject to collection.
`
`Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please
`submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes
`with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or
`other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt
`with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another
`Filing Receipt incorporating the requested corrections provided that the request is grantable.
`
`lnventor(s)
`
`Ben Merritt, San Clemente, CA;
`Jacqueline Macias, Fullerton, CA;
`Brian Michael Strauss, San Clemente, CA;
`Thomas Tu, Louisville, KY;
`John Coleman Thress, Capistrano Beach, CA;
`Paul Lubock, Monarch Beach, CA;
`
`Applicant( s)
`
`lnari Medical, Inc., Irvine, CA;
`
`Power of Attorney: The patent practitioners associated with Customer Number 25096
`
`Domestic Priority data as claimed by applicant
`This application is a CON of 18/167,757 02/10/2023
`which is a CON of 17/976,711 10/28/2022
`which is a CON of 17/865,315 07/14/2022 PAT 11,642,209
`which is a CON of 16/536, 185 08/08/2019 PAT 11,559,382
`which claims benefit of 62/718,269 08/13/2018
`and claims benefit of 62/718,248 08/13/2018
`
`Foreign Applications for which priority is claimed (You may be eligible to benefit from the Patent Prosecution
`Highway program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
`Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to
`foreign priority. See 37 CFR 1.55 and 1.76.
`
`page 1 of 4
`
`-11-
`
`

`

`Permission to Access Application via Priority Document Exchange: Yes
`
`Permission to Access Search Results: Yes
`
`Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as
`appropriate.
`
`If Required, Foreign Filing License Granted: 07/17/2023
`The country code and number of your priority application, to be used for filing abroad under the Paris Convention,
`is US 18/342,553
`Projected Publication Date: 10/26/2023
`Non-Publication Request: No
`Early Publication Request: No
`Title
`
`SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED DEVICES AND METHODS
`
`Preliminary Class
`
`606
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No
`
`PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES
`
`Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no
`effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent
`in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international
`application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same
`effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing
`of patent applications on the same invention in member countries, but does not result in a grant of "an international
`patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent
`protection is desired.
`
`Almost every country has its own patent law, and a person desiring a patent in a particular country must make an
`application for patent in that country in accordance with its particular laws. Since the laws of many countries differ
`in various respects from the patent law of the United States, applicants are advised to seek guidance from specific
`foreign countries to ensure that patent rights are not lost prematurely.
`
`Applicants also are advised that in the case of inventions made in the United States, the Director of the US PTO must
`issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application
`serves as a request for a foreign filing license. The application's filing receipt contains further information and
`guidance as to the status of applicant's license for foreign filing.
`
`Applicants may wish to consult the US PTO booklet, "General Information Concerning Patents" (specifically, the
`section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign
`patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it
`can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.
`
`page 2 of 4
`
`-12-
`
`

`

`For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish
`to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative,
`this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific
`countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may
`call the U.S. Government hotline at 1-866-999-HAL T (1-866-999-4258).
`
`LICENSE FOR FOREIGN FILING UNDER
`
`Title 35, United States Code, Section 184
`
`Title 37, Code of Federal Regulations, 5.11 & 5.15
`
`GRANTED
`
`The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where
`the conditions for issuance of a license have been met, regardless of whether or not a license may be required as
`set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier
`license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The
`date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under
`37 CFR 5.13 or 5.14.
`
`This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless
`it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This
`license is not retroactive.
`
`The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter
`as imposed by any Government contract or the provisions of existing laws relating to espionage and the national
`security or the export of technical data. Licensees should apprise themselves of current regulations especially with
`respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of
`State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and
`Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of
`Treasury (31 CFR Parts 500+) and the Department of Energy.
`
`NOT GRANTED
`
`No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING
`LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12,
`if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed
`from the filing date of this application and the licensee has not received any indication of a secrecy order under 35
`U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).
`
`SelectUSA
`
`The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for
`business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources
`and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to
`promote and facilitate business investment. SelectUSA provides information assistance to the international investor
`
`page 3 of 4
`
`-13-
`
`

`

`community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states,
`and regions competing for global investment; and counsels U.S. economic development organizations on investment
`attraction best practices. To learn more about why the United States is the best country in the world to develop
`technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call
`+ 1-202-482-6800.
`
`page 4 of 4
`
`-14-
`
`

`

`UNITED STATES PATENT AND TRADEMARK 0FFIGE
`
`APPLICATION NUMBER
`18/342,553
`
`FILING OR 371(C) DATE
`06/27/2023
`
`25096
`PERKINS COIE LLP - SEA General
`PATENT-SEA
`P.O. BOX 1247
`SEATTLE, WA98111-1247
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Vrrginia 22313-1450
`www.uspto.gov
`
`FIRST NAMED APPLICANT
`Ben Merritt
`
`ATTY. DOCKET NO./TITLE
`111552.8018.USl 1
`CONFIRMATION NO. 6799
`37 CFR 1.48 ACKNOWLEDGEMENT
`LETTER
`
`111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111
`*OC000000069902918*
`
`Date Mailed: 03/20/2024
`
`NOTICE OF ACCEPTANCE OF REQUEST UNDER 37 CFR 1.48(a)
`
`This is in response to the applicant's request under 37 CFR 1.48(a) submitted on 03/14/2024.
`
`The request under 37 CFR 1.48(a) to correct the inventorship, to correct or update the name of an inventor, or to
`correct the order of names of joint inventors is accepted.
`
`Questions about the contents of this notice and the
`requirements it sets forth should be directed to the Office
`of Data Management, Application Assistance Unit, at
`(571) 272-4000 or (571) 272-4200 or 1-888-786-0101.
`
`/dtdinh/
`
`page 1 of 1
`
`-15-
`
`

`

`Docket No.: 111552.8018.USll
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Application of:
`Ben Merritt et al.
`
`Application No.: 18/342,553
`
`Confirmation No.: 6799
`
`Filed: June 27, 2023
`
`Art Unit: 3781
`
`For: SYSTEM FOR TREATING EMBOLISM AND
`ASSOCIATED DEVICES AND METHODS
`
`Examiner: Eric Rassavong
`
`COMMENTS ON STATEMENT OF REASONS FOR ALL